APON(SZ:300753)2022-12-18 23:10Group 1: Product Demand and Market Trends - The nasal irrigation for COVID-19 prevention has been recognized by experts, with significant demand expected post-pandemic [1] - Sales of nasal spray products surged after the relaxation of COVID-19 restrictions in Hong Kong, although complete comparative data is not yet available [2] - The company has sold over 30 million bottles of nasal care products, indicating a leading market share [3] Group 2: Financial Performance and Challenges - Revenue growth for nasal care products in the first three quarters of the year has slowed due to the impact of COVID-19 restrictions in Shanghai [2] - The company’s anesthetic depth monitoring device generated sales of over 4 million yuan in 2021, primarily targeting tertiary hospitals [3] - The chronic pain management market has a significant potential, with approximately 170 million pain patients in China [4] Group 3: Competitive Landscape and Strategies - The nasal care product market is competitive, with the company focusing on clinical research and brand promotion [2] - The company plans to expand its anesthetic depth monitoring device market share, currently dominated by imported brands [3] - The postoperative analgesia market is projected to grow, with the company holding a market share of about 16% in this segment [5] Group 4: Future Outlook - The market for postoperative analgesia is expected to grow by approximately 10% annually, driven by increased surgical volumes and improved analgesia rates [5] - The electronic drug delivery pump market is estimated to be around 1.5 billion yuan, with future growth expected to reach 3 billion yuan [5]